MEDU-47. PEROXIREDOXIN1 IS A THERAPEUTIC TARGET IN GROUP-3 MEDULLOBLASTOMAS

Group-3 Medulloblastomas (MBL) has the worst prognosis due to its resistance to radiation and chemotherapy with a 5-year survival of 30%. Thus, there is an urgent need to elucidate targets that can sensitize Group-3 tumors to conventional treatments. We identified PRDX1 as a candidate therapeutic ta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Sajesh, Babu, Omar, Refaat, Jarmasz, Jessica, Stirton, Hannah, Morrison, Ludivine, Wang, W, Pu, J, Sun, HD, Bigio, Marc Del, Werbowetski-Ogilvie, Tamra, Wolfl, Matthais, Remke, Marc, Taylor, Michael, Eberhart, Charles, Symons, Marc, Ruggieri, Rosamaria, Vanan, Magimairajan Issai
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5475172/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox083.196
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados